OBJECTIVE: Study of the lipid profile in patients infected with HIV treated with different combinations of high activity anti-retroviral therapy (HAART). DESIGN AND METHODS: A retrospective cohort study of the lipid profile in patients undergoing HAART. The study analyzes the evolution of concentrations of triglycerides (TG), total cholesterol (TC), LDL-cholesterol (LDLc) and HDL-cholesterol (HDLc) in a period of at least 3 years of treatment. From a total of 750 clinical cases analyzed in Hospital Joaquim Urbano (Oporto, Portugal) 124 patients were selected for this study. RESULTS: After 3 years of treatment, we observed the development of dyslipidaemia by increases in TG (17%), TC (29%) and LDLc (9%), particularly in patients treated with a combination of drugs which included protease inhibitors (PI). Moreover, the non-nucleoside reverse transcriptase inhibitors (NNRTI) were associated with better lipid profile. The increase of 46% in HDLc was the most surprising finding. CONCLUSIONS: The results indicate that patients with HAART have a more atherogenic lipidic profile with increased TC, LDLc and TG levels. Since the effectiveness of NNRTI is similar to that of PI, but with a smaller atherogenic profile, it should be the first choice drug to be selected in the HIV treatment.
OBJECTIVE: Study of the lipid profile in patients infected with HIV treated with different combinations of high activity anti-retroviral therapy (HAART). DESIGN AND METHODS: A retrospective cohort study of the lipid profile in patients undergoing HAART. The study analyzes the evolution of concentrations of triglycerides (TG), total cholesterol (TC), LDL-cholesterol (LDLc) and HDL-cholesterol (HDLc) in a period of at least 3 years of treatment. From a total of 750 clinical cases analyzed in Hospital Joaquim Urbano (Oporto, Portugal) 124 patients were selected for this study. RESULTS: After 3 years of treatment, we observed the development of dyslipidaemia by increases in TG (17%), TC (29%) and LDLc (9%), particularly in patients treated with a combination of drugs which included protease inhibitors (PI). Moreover, the non-nucleoside reverse transcriptase inhibitors (NNRTI) were associated with better lipid profile. The increase of 46% in HDLc was the most surprising finding. CONCLUSIONS: The results indicate that patients with HAART have a more atherogenic lipidic profile with increased TC, LDLc and TG levels. Since the effectiveness of NNRTI is similar to that of PI, but with a smaller atherogenic profile, it should be the first choice drug to be selected in the HIV treatment.
Authors: Supriya Krishnan; Jeffrey T Schouten; Benjamin Atkinson; Todd T Brown; David A Wohl; Grace A McComsey; Marshall J Glesby; Cecilia Shikuma; Richard Haubrich; Denise L Jacobson Journal: J Acquir Immune Defic Syndr Date: 2015-01-01 Impact factor: 3.731
Authors: Lori A Gordon; Christine Y Malati; Colleen Hadigan; Mary McLaughlin; Raul M Alfaro; Mónica M Calderón; Joseph A Kovacs; Scott R Penzak Journal: Pharmacotherapy Date: 2016-01 Impact factor: 4.705
Authors: Rebecca B Marino; Lawrence A Kingsley; Shehnaz K Hussain; Jay H Bream; Sudhir Penogonda; Priya Duggal; Jeremy J Martinson Journal: BMC Res Notes Date: 2015-11-21
Authors: Damariz Marín-Palma; Gustavo A Castro; Jaiberth A Cardona-Arias; Silvio Urcuqui-Inchima; Juan C Hernandez Journal: Front Immunol Date: 2018-06-14 Impact factor: 7.561